DIMA Biotech
SKU(재고 관리 코드):
Anti-CXCR7 antibody(DMC443); IgG1 Chimeric mAb
Anti-CXCR7 antibody(DMC443); IgG1 Chimeric mAb
가격·납기 및 기술자료를 확인해 드립니다.
제품 규격과 수량을 선택한 후 견적을 요청해 주세요. 대체품 검토와 SDS·COA·데이터시트 요청도 함께 접수할 수 있습니다.
이 제품 견적 요청대표번호 070-8028-3500 · info@rndmate.com
| Clone ID |
DMC443 |
|---|---|
| Target | |
| Synonyms |
Atypical chemokine receptor 3;CXC-R7;CXCR-7;Chemokine orphan receptor 1;G-protein coupled receptor 159;RDC-1 |
| Host Species |
Rabbit |
| Description |
Anti-CXCR7 antibody(DMC443); IgG1 Chimeric mAb |
| Delivery |
In Stock |
| Uniprot ID |
P25106 |
| IgG type |
Rabbit/Human Fc chimeric IgG1 |
| Clonality |
Monoclonal |
| Reactivity |
Human |
| Applications |
Flow Cyt |
| Recommended Dilutions |
Flow Cyt 1:100 |
| Purification |
Purified from cell culture supernatant by affinity chromatography |
| Formulation & Reconstitution |
Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Storage&Shipping |
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background |
This gene encodes a member of the G-protein coupled receptor family. Although this protein was earlier thought to be a receptor for vasoactive intestinal peptide (VIP); it is now considered to be an orphan receptor; in that its endogenous ligand has not been identified. The protein is also a coreceptor for human immunodeficiency viruses (HIV). Translocations involving this gene and HMGA2 on chromosome 12 have been observed in lipomas. |
| Usage |
Research use only |
| Conjugate |
Unconjugated |
| DIMA Disclaimer |
All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement. |
Share
